131 related articles for article (PubMed ID: 29808694)
1. [Pilot Study on MicroRNAs as Biomarkers of Response to Sunitinib Treatment in Patients with Metastatic Renall Cell Carcinoma].
Kováčová J; Juráček J; Poprach A; Büchler T; Kopecký J; Fiala O; Svoboda M; Lojová M; Slabý O
Klin Onkol; 2018; 31(Supplementum1):161-162. PubMed ID: 29808694
[TBL] [Abstract][Full Text] [Related]
2. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O
Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
[TBL] [Abstract][Full Text] [Related]
4. [MicroRNAs in Prediction of Response to Radiotherapy in Head and Neck Cancer Patients - Pilot Study].
Ahmad P; Slavík M; Šána J; Hermanová M; Šlampa P; Smilek P; Kazda T; Slabý O
Klin Onkol; 2018; 31(Supplementum1):137-139. PubMed ID: 29808687
[TBL] [Abstract][Full Text] [Related]
5. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.
Kovacova J; Juracek J; Poprach A; Kopecky J; Fiala O; Svoboda M; Fabian P; Radova L; Brabec P; Buchler T; Slaby O
Cancer Genomics Proteomics; 2019; 16(5):353-359. PubMed ID: 31467229
[TBL] [Abstract][Full Text] [Related]
6. [Urinary MicroRNAs as Potential Biomarkers of Bladder Cancer].
Juráček J; Staník M; Peltanová B; Adamcová S; Doležel J; Fedorko M; Radová L; Slabý O
Klin Onkol; 2018; 31(Supplementum1):155-157. PubMed ID: 29808692
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.
Vitruk Yu V; Semko SL; Voylenko OA; Pikul MV; Borikun TV; Zadvornyi TV; Yalovenko TM; Stakhovsky EO; Rossylna OV
Exp Oncol; 2021 Jun; 43(2):98-103. PubMed ID: 34190510
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
10. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Metastatic Renal Cell Carcinoma].
Richter I; Dvořák J
Klin Onkol; 2018; 31(2):110-116. PubMed ID: 29708353
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.
García-Donas J; Beuselinck B; Inglada-Pérez L; Graña O; Schöffski P; Wozniak A; Bechter O; Apellániz-Ruiz M; Leandro-García LJ; Esteban E; Castellano DE; González Del Alba A; Climent MA; Hernando S; Arranz JA; Morente M; Pisano DG; Robledo M; Rodriguez-Antona C
JCI Insight; 2016 Jul; 1(10):e86051. PubMed ID: 27699216
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
[TBL] [Abstract][Full Text] [Related]
14. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
[TBL] [Abstract][Full Text] [Related]
15. [Usage of Cerebrospinal Fluid for microRNA Analysis].
Kopková A; Šána J; Večeřa M; Knoflíčková D; Smrčka M; Slabý O; Fadrus P
Klin Onkol; 2018; 31(Supplementum1):158-160. PubMed ID: 29808693
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Polena H; Creuzet J; Dufies M; Sidibé A; Khalil-Mgharbel A; Salomon A; Deroux A; Quesada JL; Roelants C; Filhol O; Cochet C; Blanc E; Ferlay-Segura C; Borchiellini D; Ferrero JM; Escudier B; Négrier S; Pages G; Vilgrain I
Br J Cancer; 2018 May; 118(9):1179-1188. PubMed ID: 29563634
[TBL] [Abstract][Full Text] [Related]
18. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
van der Zanden LFM; Vermeulen SH; Oskarsdottir A; Maurits JSF; Diekstra MHM; Ambert V; Cambon-Thomsen A; Castellano D; Fritsch A; Garcia Donas J; Guarch Troyas R; Guchelaar HJ; Hartmann A; Hulsbergen-van de Kaa C; Jaehde U; Junker K; Martinez-Cardus A; Masson G; Oosterwijk-Wakka J; Radu MT; Rafnar T; Rodriguez-Antona C; Roessler M; Ruijtenbeek R; Stefansson K; Warren A; Wessels L; Eisen T; Kiemeney LALM; Oosterwijk E
Urol Oncol; 2017 Aug; 35(8):529.e9-529.e16. PubMed ID: 28385611
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
Mouillet G; Fritzsch J; Paget-Bailly S; Pozet A; Es-Saad I; Meurisse A; Vernerey D; Mouyabi K; Berthod D; Bonnetain F; Anota A; Thiery-Vuillemin A
Health Qual Life Outcomes; 2019 Feb; 17(1):25. PubMed ID: 30717745
[TBL] [Abstract][Full Text] [Related]
20. Use of Salivary MicroRNAs for Diagnosis of Solid Cancers.
Kubíčková A; Slabý O
Klin Onkol; 2018; 31(4):249-259. PubMed ID: 30541306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
